When
Where
Oslo Cancer Cluster Innovation Park
Organizer
Norway has strong clinical expertise, patient access and infrastructure relevant for radiopharmaceutical and theranostics clinical trials. However, these capabilities are not always sufficiently visible, accessible, or coordinated across the ecosystem.
This meeting brings together hospitals, clinical researchers, emerging radiopharma companies, global pharma and ecosystem partners to learn from international examples, share recent initiatives, and discuss gaps and opportunities positioning Norway as a preferred destination for radiopharmaceutical trials.
Speaker: Prof. Frederik L. Giesel, Chair of Nuclear Medicine, University Hospital Düsseldorf, see profile below
Speakers from Norway´s clinical milieu present initiatives at the intersection of nuclear medicine, oncology and radiopharmaceutical research and how cross-disciplinary collaboration is expanding the country's capacity for radiopharmaceutical research and trials. They will discuss what these initiatives offer to the broader ecosystem, and where opportunities for deeper partnership lie.
Emerging Norwegian companies and global pharma present their R&D, their experience of the Norwegian clinical ecosystem, and what they need to accelerate or locate their next studies here. Together, their perspectives draw a clear picture of where Norway stands and what it would take to make it a preferred destination for radiopharmaceutical clinical trials.
Closing panel bringing together perspectives from clinic, industry and investment to synthesize the day's key insights into concrete priorities and how these can be addressed jointly going forward.
The full program will be announced in the coming weeks.
Hosted by Oslo Cancer Cluster and the National Expert Group for Radiotherapy Research (NERR) and supported by the Syklotronsenter.
The event is the first of two complementary ecosystem events in 2026 and potentially a start to a meeting series (co)hosted by different members and partners in the OUS / UiO RLT- and theranostics initiative coordinated by Caroline Stokke and initiated via the Oslo Science City Gravitational Fields Initiative.
The second event will be hosted by the Syklotronsenter and takes place on June 10th, 2026.
Contacts:
Jutta Heix, jh@oslocancercluster.no for OCC
Ase Bratland, BRT@ous-hf.no and Berit Bø, BBH@ous-hf.no for NERR
Prof. Dr. Frederik L. Giesel, MD, MBA, Chair, Department of Nuclear Medicine, University Hospital Düsseldorf
Prof. Frederik Giesel is one of Europe's leading clinical scientists in radiopharmaceutical oncology and theranostics. As Chair of Nuclear Medicine at the University Hospital Düsseldorf (Heinrich-Heine-University), he leads one of Germany's foremost theranostics programs, integrating PSMA and FAPI-based diagnostics, radioligand therapy and early access to novel alpha-emitting agents in routine clinical and trial settings.
Prof. Giesel is co-inventor of FAPI-46, FAPI-74 and [¹⁸F]PSMA-1007 which is among the most widely used radiopharmaceutical tracers in clinical practice today. He has been instrumental in translating these compounds from academic discovery into licensed, commercially available agents. His publication record spans more than 550 peer-reviewed papers (H-index >50), with landmark contributions to FAPI PET/CT in breast cancer, PSMA radioligand therapy in prostate cancer, and the first standardized reporting framework for FAP-targeted imaging (FAP-RADS, 2025).
Beyond his clinical and scientific work, Prof. Giesel brings a direct understanding of the academia–industry interface, having collaborated across the full development chain from radiochemistry and GMP production through to Phase I/II trials and commercial licensing. He serves as Co-Chair of the Scientific Advisory Board of the ICPO Foundation and as Scientific Advisor to Telix Pharmaceuticals, SOFIE Biosciences, ABX GmbH and Alpha Fusion.